Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Compass Therapeutics, Inc. - Common Stock (NQ:CMPX)

0.8191 +0.0603 (+7.95%)
Delayed Quote Updated: 2:26 PM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Compass Therapeutics, Inc. - Common Stock

News headline image
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
From Equity Insider
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
From Pomerantz LLP
Via GlobeNewswire
News headline image
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers (BTC), and the Clearance of a Key Clinical Hurdle
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics to Present at the Citi 16th Annual Biopharma Virtual Conference
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.
From Compass Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.